MRTX - Mirati CFO leaving company in wake of CEO departure
2023-08-23 16:37:15 ET
More on Mirati Therapeutics
- Mirati Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation
- Mirati Therapeutics, Inc. ( MRTX ) Q2 2023 Earnings Call Transcript
- Mirati Therapeutics: EU Rejection Clouds Krazati's Prospects
- Citi upgrades Mirati to buy; cites valuation, leadership change
- Mirati Therapeutics up 9% on pricing $300M upsized equity offering
- Mirati fails to win EU backing for lung cancer therapy
- Mirati tumbles after study failure for cancer drug; Oppenheimer upgrades
- Seeking Alpha’s Quant Rating on Mirati Therapeutics
- Earnings data for Mirati Therapeutics
For further details see:
Mirati CFO leaving company in wake of CEO departure